JP2008514717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514717A5 JP2008514717A5 JP2007534728A JP2007534728A JP2008514717A5 JP 2008514717 A5 JP2008514717 A5 JP 2008514717A5 JP 2007534728 A JP2007534728 A JP 2007534728A JP 2007534728 A JP2007534728 A JP 2007534728A JP 2008514717 A5 JP2008514717 A5 JP 2008514717A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- group
- seq
- amino acid
- bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 239000000203 mixture Substances 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- -1 carbobenzoxyl group Chemical group 0.000 claims 5
- 125000001165 hydrophobic group Chemical group 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 241000711549 Hepacivirus C Species 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000034217 membrane fusion Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003068 static effect Effects 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61428004P | 2004-09-29 | 2004-09-29 | |
| US60/614,280 | 2004-09-29 | ||
| PCT/US2005/034777 WO2006039326A2 (en) | 2004-09-29 | 2005-09-26 | Inhibitors of hepatitits c virus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008514717A JP2008514717A (ja) | 2008-05-08 |
| JP2008514717A5 true JP2008514717A5 (https=) | 2008-11-13 |
| JP4980915B2 JP4980915B2 (ja) | 2012-07-18 |
Family
ID=36143015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534728A Expired - Fee Related JP4980915B2 (ja) | 2004-09-29 | 2005-09-26 | Ｃ型肝炎ウイルスのインヒビター |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7381705B2 (https=) |
| EP (1) | EP1797112B1 (https=) |
| JP (1) | JP4980915B2 (https=) |
| AT (1) | ATE474587T1 (https=) |
| AU (1) | AU2005292135B2 (https=) |
| CA (1) | CA2582095A1 (https=) |
| DE (1) | DE602005022463D1 (https=) |
| ES (1) | ES2349153T3 (https=) |
| PL (1) | PL1797112T3 (https=) |
| PT (1) | PT1797112E (https=) |
| WO (1) | WO2006039326A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009510122A (ja) * | 2005-09-29 | 2009-03-12 | ザ スクリプス リサーチ インスティテュート | ウイルスペプチドおよびフラビウイルス科のウイルスに対してウイルス感染を阻害するためのその使用 |
| WO2008124176A2 (en) | 2007-04-10 | 2008-10-16 | The Administrators Of The Tulane Educational Fund | Soluble and membrane-anchored forms of lassa virus subunit proteins |
| WO2009021063A2 (en) * | 2007-08-06 | 2009-02-12 | The Regents Of The University Of California | Composition and method of use for hcv immunization |
| WO2009030872A1 (en) * | 2007-09-07 | 2009-03-12 | Mats Axel Atterdag Persson | Materials and methods for the treatment of hepatitis c |
| CA2698666A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
| CA2658714A1 (en) | 2009-03-17 | 2010-09-17 | Thomas Krey | Hcv-derived polypeptides and uses thereof |
| WO2013050048A2 (en) | 2011-10-07 | 2013-04-11 | Skau Aps | Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses |
| CN104324361A (zh) * | 2014-05-16 | 2015-02-04 | 中国疾病预防控制中心病毒病预防控制所 | 丙型肝炎病毒(hcv)细胞进入抑制肽zte2序列及应用 |
| CN109232721B (zh) * | 2018-09-26 | 2021-06-29 | 广州市第八人民医院 | Hcv包膜蛋白高度保守区域的肽段418-429及其用途 |
| AU2020323462A1 (en) * | 2019-07-26 | 2022-03-10 | The Scripps Research Institute | Engineered HCV E2 immunogens and related vaccine compositions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0185373B1 (ko) * | 1989-03-17 | 1999-05-01 | 로버트 피. 블랙버언 | Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용 |
| US5747239A (en) * | 1990-02-16 | 1998-05-05 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines |
| EP0992580B1 (en) * | 1993-11-04 | 2005-03-09 | Innogenetics N.V. | Immunodominant human T-cell epitopes of Hepatitis C virus |
| US6127116A (en) * | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6037348A (en) * | 1996-02-09 | 2000-03-14 | Eli Lilly And Company | Inhibition of viral replication |
| JP2001514508A (ja) * | 1997-03-05 | 2001-09-11 | ユニバーシティー オブ ワシントン | Ｃ型肝炎ウイルスの複製を選択的に抑制する薬剤を同定するための新規なスクリーニング法 |
| US6153421A (en) * | 1997-07-18 | 2000-11-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Cloned genomes of infectious hepatitis C viruses and uses thereof |
| US6127166A (en) * | 1997-11-03 | 2000-10-03 | Bayley; Hagan | Molluscan ligament polypeptides and genes encoding them |
| US7091324B2 (en) * | 1998-11-05 | 2006-08-15 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
| EP1178116A1 (en) | 2000-08-03 | 2002-02-06 | Hybrigenics S.A. | Sid nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof |
| JP5175417B2 (ja) * | 2000-08-17 | 2013-04-03 | トリペップ アクチ ボラゲット | リバビリンを含むワクチンおよびその使用方法 |
| US20030232745A1 (en) * | 2001-06-26 | 2003-12-18 | Olson William C. | Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection |
| US7022323B2 (en) * | 2001-06-26 | 2006-04-04 | Progenics Pharmaceuticals, Inc. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| DK1558276T3 (da) | 2002-11-08 | 2012-10-22 | Univ Tulane | Flavivirus-fusionsinhibitorer |
| EP1638993A4 (en) * | 2003-06-10 | 2007-05-09 | Univ Melbourne | IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF |
-
2005
- 2005-09-26 AT AT05814026T patent/ATE474587T1/de not_active IP Right Cessation
- 2005-09-26 JP JP2007534728A patent/JP4980915B2/ja not_active Expired - Fee Related
- 2005-09-26 WO PCT/US2005/034777 patent/WO2006039326A2/en not_active Ceased
- 2005-09-26 ES ES05814026T patent/ES2349153T3/es active Active
- 2005-09-26 CA CA002582095A patent/CA2582095A1/en not_active Abandoned
- 2005-09-26 DE DE602005022463T patent/DE602005022463D1/de active Active
- 2005-09-26 EP EP05814026A patent/EP1797112B1/en not_active Not-in-force
- 2005-09-26 AU AU2005292135A patent/AU2005292135B2/en not_active Ceased
- 2005-09-26 PL PL05814026T patent/PL1797112T3/pl unknown
- 2005-09-26 US US11/235,672 patent/US7381705B2/en not_active Expired - Fee Related
- 2005-09-26 PT PT05814026T patent/PT1797112E/pt unknown
-
2008
- 2008-05-19 US US12/152,964 patent/US20080241156A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3998077B1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| CA2187083C (fr) | Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation | |
| JP5791900B2 (ja) | Ｂ型肝炎ウイルス（ＨＢＶ）の疎水性改変ｐｒｅＳ由来ペプチドならびにＨＢＶ侵入インヒビターおよびＨＤＶ侵入インヒビターとしてのそれらの使用 | |
| DK2519250T3 (en) | Interferon analogs | |
| US11180534B1 (en) | Compositions and methods for treating SARS-CoV-2 infections | |
| WO2009046220A3 (en) | Lipopeptides for delivery of nucleic acids | |
| JP2008514717A5 (https=) | ||
| JP2018515088A5 (https=) | ||
| JP2013543497A5 (https=) | ||
| RU2016120641A (ru) | Новые полипептиды | |
| JP2011518179A5 (https=) | ||
| US20080241156A1 (en) | Inhibitors of hepatitis C virus | |
| JP2016512213A5 (https=) | ||
| ATE350049T1 (de) | Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1 | |
| JP2016516734A5 (https=) | ||
| JP6811190B2 (ja) | プロテアーゼ耐性脂質付加ｇｌｐ−１類似体 | |
| US20050152917A1 (en) | Hepatitis B virus treatment | |
| US7151163B2 (en) | Antiviral agents for the treatment, control and prevention of infections by coronaviruses | |
| AU2002247084A1 (en) | Hepatitis B virus treatment | |
| JP4307838B2 (ja) | Ｇｐ１２０ウイルスタンパク質に対して親和性を示すペプチド、およびその使用 | |
| JP2006507328A5 (https=) | ||
| Kim et al. | An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus | |
| CN113876939A (zh) | 登革次单位疫苗组成物 | |
| JP2022553367A (ja) | 非アルコール性脂肪肝の治療 | |
| ZA200509512B (en) | Antiviral agents for the treatment, control and prevention of infections by coronaviruses |